Basic information Safety Supplier Related

Icotinib (Hydrochloride)

Basic information Safety Supplier Related

Icotinib (Hydrochloride) Basic information

Product Name:
Icotinib (Hydrochloride)
Synonyms:
  • CS-1906
  • CS-1016
  • Icotinib Hydrochloride (BPI-2009)
  • Icotinib (Hydrochloride)
  • N-(3-Ethynylphenyl)-7,8,10,11,13,14-hexahydro-[1,4,7,10]tetraoxacyclododecino[2,3-g]quinazolin-4-amine hydrochloride
  • N-(3-Ethynylphenyl)-7,8,10,11,13,14-hexahydro-[1,4,7,10]tetraoxacyclododecino[2,3-g]quinazolin-4-amine hydrochloride Icotinib (Hydrochloride)
  • Icotinib HCl
  • Icotinib (Hydrochloride) impurity
CAS:
1204313-51-8
MF:
C22H22ClN3O4
MW:
427.89
EINECS:
1592732-453-0
Product Categories:
  • Inhibitors
Mol File:
1204313-51-8.mol
More
Less

Icotinib (Hydrochloride) Chemical Properties

storage temp. 
Store at -20°C
solubility 
Soluble in DMSO
form 
Powder
color 
White to off-white
More
Less

Icotinib (Hydrochloride) Usage And Synthesis

Clinical Use

Icotinib hydrochloride, developed by the Chinese pharmaceutical company Zhejiang Bata Pharma Inc., is a potent small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for the treatment of non-small cell lung cancer (NSCLC). It was first approved by the SFDA of China, and launched under the brand name Conmana in the middle of 2011, representing an important milestone for Chinese pharmaceutical research and development. As the third EGFR-TKI drug targeting NSCLS therapy, icotinib hydrochloride possesses a similar structure to gefitinib (Iressa, AstraZeneca) and erlotinib (Tarceva, OST & Roche). Interestingly, a randomized, double-blind phase III clinical study of icotinib versus gefitinib in 399 patients with advanced NSCLC demonstrated that icotinib provides similar efficacy to gefitinib, but with better tolerability in NSCLC patients previously treated with one or two chemotherapy agents.

Synthesis

Icotinib was prepared by a similar process approach to that of erlotinib. Beginning from commercially available 2,20-(ethylenedioxy)diethanol (162), bis-tosylation to 163, followed by bis-alkylation with commercially available catechol derivative 164 provided crown-4-ether 165 in 96% yield. Nitration of polyether 165 using concentrated nitric acid and concentrated sulfuric acid provided nitroarene 166 in 65% yield. Reduction of the nitroarene under catalytic hydrogenation conditions gave amine 167 in 85% yield. Condensation of the amine 167 with formamide in the presence of ammonium formate afforded quinazolinone 168 in 80% yield. The chlorination of 168 using POCl3 furnished quinazolyl chloride 169 in 77% yield. The treatment of chloride 169 with amine 170 followed by the HCl salt formation produced icotinib hydrochloride (XIV) in good yield.

target

EGFR

Icotinib (Hydrochloride)Supplier

Beida pharmaceutical co., Ltd. Gold
Tel
0571-89263217
Email
li.liu@bettapharma.com
Shanghai Boyle Chemical Co., Ltd.
Tel
Email
sales@boylechem.com
Dalian Meilun Biotech Co., Ltd.
Tel
0411-62910999 13889544652
Email
meilunui@163.com
Haoyuan Chemexpress Co., Ltd.
Tel
021-58950125
Email
info@chemexpress.com
Guangzhou Isun Pharmaceutical Co., Ltd
Tel
020-39119399 18927568969
Email
isunpharm@qq.com
More
Less